---
title: "Targeting ANGPTL4/NRP1/ABL1/RAD51 Axis Reverses Cisplatin Resistance in Head and Neck Cancer"
id: "pnas-67-targeting-the-angptl4-nrp1-abl1-rad51-axis-reverses-cisplatin-resistance-by-impairing-dna-damage-repair-in-head-and-neck-cancer"
canonical_url: "https://medichelpline.com/clinical-feed/pnas-67-targeting-the-angptl4-nrp1-abl1-rad51-axis-reverses-cisplatin-resistance-by-impairing-dna-damage-repair-in-head-and-neck-cancer"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "PNAS"
source_url: "https://www.pnas.org/doi/abs/10.1073/pnas.2510265123?af=R"
published_at: "2026-03-26T07:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Targeting ANGPTL4/NRP1/ABL1/RAD51 Axis Reverses Cisplatin Resistance in Head and Neck Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pnas-67-targeting-the-angptl4-nrp1-abl1-rad51-axis-reverses-cisplatin-resistance-by-impairing-dna-damage-repair-in-head-and-neck-cancer
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** PNAS
- **Source URL:** [Original Journal Publication](https://www.pnas.org/doi/abs/10.1073/pnas.2510265123?af=R)
- **Published At:** 2026-03-26T07:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Proceedings of the National Academy of Sciences, Volume 123, Issue 13, March 2026. SignificanceHere, we identify a molecular pathway that drives cisplatin resistance in head and neck squamous cell carcinoma (HNSCC). The angiogenic factor angiopoietin-like 4 (ANGPTL4) engages Neuropilin1 to activate ABL1, which in turn phosphorylates and ...
## Clinical Analysis & Structured Key Points
PNAS published a clinical update in Research Highlights on 26 Mar 2026. The item focuses on Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and neck cancer. Review the original article for the full source wording and details.
## Related Clinical Research

- [Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial](https://medichelpline.com/clinical-feed/bmj-open-19-adjuvant-short-course-radiotherapy-combined-with-chemotherapy-and-a-pd-1-inhibitor-for-resected-mucosal-melanoma-study-protocol-for-a-single-arm-prospective-phase-ii-trial.md)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [SLFN11 as a biomarker of cisplatin sensitivity in pediatric solid tumors](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-slfn11-enhances-cisplatin-sensitivity-in-pediatric-cancer-via-activation-of.md)
- [Avoiding Cardiac Toxicity with Immune Checkpoint Inhibitors: Safety Review (Title Only Available)](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-avoidance-of-cardiac-toxicity-during-the-application-of-immune-checkpoint.md)
- [PCK2 inhibition restores cisplatin sensitivity in NSCLC by inducing ferroptosis](https://medichelpline.com/clinical-feed/pubmed-42599961.md) (DOI: 10.1096/fj.202602464R)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.